Mineralys Therapeutics (MLYS) Insider Trading & Ownership $12.34 +0.51 (+4.31%) (As of 12/20/2024 05:16 PM ET) Add Compare Share Share Insider Trades Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Mineralys Therapeutics (NASDAQ:MLYS) Insider Buying and Selling ActivityCurrentInsider OwnershipPercentage33.24%Number OfInsiders Buying(Last 12 Months)1Amount OfInsider Buying(Last 12 Months)$7.50 MNumber OfInsiders Selling(Last 12 Months)4Amount OfInsider Selling(Last 12 Months)$9.94 M Get MLYS Insider Trade Alerts Want to know when executives and insiders are buying or selling Mineralys Therapeutics stock? Sign up for InsiderTrades.com's daily newsletter to get the latest insider transactions delivered to your inbox daily. Email Address MLYS Insider Buying and Selling by Quarter Ad Wealthpin ProVacuum up cash with these special trades? Have you ever heard about a “volatility vacuum?” Most people haven’t. It all revolves around this formula right here. Now, the most important thing is that this equation — when applied to certain tickers at a certain time each month —- can trigger these “volatility vacuums.” And when that happens, anyone has the shot at sucking out payouts of $290, $350, even $1,350 in as little as 24 hours. (With just a $1k starting stake!) Granted, there were smaller wins and those that did not work out but best of all, we can know exactly when these opportunities will hit. I’ve used this info to create a Cash Calendar that lays out the precise dates of these payouts. And I’m sending it for FREE to anyone who joins me during my FREE training right here. Mineralys Therapeutics Insider and Congressional Trades History Insiders and Members of Congress Insiders Only Members of Congress Only Transaction Type Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year 2 Years 3 Years Time Frame * Start Date * End Date Export to Excel Transaction DateNameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails11/6/2024David Malcom RodmanInsiderSell25,482$15.03$382,994.46 10/11/2024Adam Scott LevyCFOSell10,757$13.57$145,972.49 10/11/2024Jon CongletonCEOSell15,271$13.52$206,463.92 7/24/2024Brian Taylor SlingsbyDirectorSell550,000$13.05$7,177,500.00 7/16/2024David Malcom RodmanInsiderSell525$15.00$7,875.00 7/11/2024Adam Scott LevyCFOSell10,757$13.14$141,346.98 Get Insider Trades Delivered To Your InboxEnter your email address below to receive a concise daily summary of insider buying activity, insider selling activity and changes in hedge fund holdings. 7/11/2024Jon CongletonCEOSell15,746$13.34$210,051.64 6/14/2024Jon CongletonCEOSell16,229$12.52$203,187.08 6/12/2024Jon CongletonCEOSell16,607$12.77$212,071.39 6/11/2024Adam Scott LevyCFOSell96,815$12.94$1,252,786.10 5/9/2024David Malcom RodmanInsiderSell100$15.00$1,500.00 2/12/2024Samsara Biocapital Gp, LlcMajor ShareholderBuy555,555$13.50$7,499,992.50 (Data available from 1/1/2013 forward) MLYS Insider Trading Activity - Frequently Asked Questions Who is on Mineralys Therapeutics's Insider Roster? The list of insiders at Mineralys Therapeutics includes Adam Scott Levy, Brian Taylor Slingsby, David Malcom Rodman, Hbm Healthcare Investments (Ca, Jon Congleton, Ra Capital Management, L.P., and Samsara Biocapital Gp, Llc. Learn more on insiders at MLYS. What percentage of Mineralys Therapeutics stock is owned by insiders? 33.24% of Mineralys Therapeutics stock is owned by insiders. Learn more on MLYS's insider holdings. Which Mineralys Therapeutics insiders have been buying company stock? The following insiders have purchased MLYS shares in the last 24 months: Adam Scott Levy ($100,000.00), Hbm Healthcare Investments (Ca ($5,000,000.00), Jon Congleton ($105,557.50), Ra Capital Management, L.P. ($20,000,000.00), and Samsara Biocapital Gp, Llc ($7,499,992.50). How much insider buying is happening at Mineralys Therapeutics? Insiders have purchased a total of 2,135,055 MLYS shares in the last 24 months for a total of $32,705,550.00 bought. Which Mineralys Therapeutics insiders have been selling company stock? The following insiders have sold MLYS shares in the last 24 months: Adam Scott Levy ($1,540,105.57), Brian Taylor Slingsby ($7,177,500.00), David Malcom Rodman ($2,404,705.17), and Jon Congleton ($831,774.03). How much insider selling is happening at Mineralys Therapeutics? Insiders have sold a total of 915,380 Mineralys Therapeutics shares in the last 24 months for a total of $11,954,084.77 sold. Mineralys Therapeutics Key ExecutivesDr. Brian Taylor Slingsby M.D. (Age 47)M.P.H., Ph.D., Founder & Executive Chairman Compensation: $69.33k1 recent tradesMr. Jon Congleton (Age 61)CEO & Director Compensation: $775.77k2 recent tradesMr. Adam Scott Levy (Age 46)CFO & Secretary Compensation: $655.58k2 recent tradesDr. David M. Rodman M.D. (Age 69)Chief Medical Officer Compensation: $726.95kMs. Cindy BerejikianExecutive Vice President of OperationsMs. Sarah FosterVice President of Human ResourcesDr. Robert McKean Ph.D.Senior Vice President of CMCMs. Danielle BradburySenior Vice President of Quality AssuranceMr. Jeffrey N. FellowsSenior Vice President of Regulatory AffairsMs. Jessica IbbitsonSenior Vice President of Clinical Operations More Insider Trading Tools from MarketBeat Related Companies AMRX Insider Buying LBPH Insider Buying LGND Insider Buying GERN Insider Buying NAMS Insider Buying IDYA Insider Buying CNTA Insider Buying WVE Insider Buying AKRO Insider Buying MIRM Insider Buying Insider Tracking Tools CEO Purchases/Sales CFO Purchases/Sales Top Insider Buying Stocks Top Insider Selling Stocks Insider Trades Screener Insider Trades Newsletter Congressional Stock Trades Insider Trading By Country U.S. Insider Trading Activity Canadian Insider Trading Activity U.K. Insider Trading Activity Australia Insider Trading Activity Latest Articles AppLovin Insiders Sell Shares: Stock Price Indicated Higher Are 2024’s Top Insider Buys a Good Bet for 2025? Bargains Galore? 3 Stocks With Insider Buying in the MillionsInsiders Keep Buying These Stocks: 2 to Buy, 1 to AvoidZeta Global Holdings Insiders Buy Stock After Short-Report This page (NASDAQ:MLYS) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mineralys Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Mineralys Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
